Atlas Trials

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Clinical trial NCT02736448 · TERMINATED

Trial details

NCT number
NCT02736448
Sponsor
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Gastro-entero-pancreatic Neuroendocrine Tumors
Start date
2016-05-01
Primary completion
2019-08-01
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.